ALEC - יחס שווי שוק להכנסות החברה Alector Inc.

The current P/S multiple demonstrates the share price's dependence on antibody test results, with the value holding at 1.60. Alector, Inc. (ALEC) develops treatments for Parkinson's and Alzheimer's diseases by activating microglia. Development relies on a staff of leading researchers with access to cutting-edge laboratories. Capital stability ensures security during the prolonged wait for clinical data.
Alector, Inc. (ALEC) - פילוחי מדדים ודוחות פיננסיים

The P/S ratio compares market capitalization to annual revenue, allowing for an assessment of business value relative to its ability to generate income. By analyzing historical P/S trends, an investor can identify whether an asset is overbought, which is critical for Alector, Inc. (ALEC), as its valuation is based on strong community confidence in its innovative immunotherapy methods for Alzheimer's disease.